Factors Associated with Severe Presentation and Mortality in ICU-Acquired Candidaemia: A 20-Year Single-Centre Retrospective Cohort
4 affiliations
- 1Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Türkiye
- 2Department of Medical Microbiology, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Türkiye
- 3Department of Biostatistics, Faculty of Medicine, Bursa Uludag University, Bursa 16000, Türkiye
- 4Department of Anesthesiology and Reanimation, School of Medicine, Uludag University, Bursa 16059, Türkiye
Abstract
Background/Objectives: The risk factors for the severe presentation (severe sepsis or septic shock) are not fully understood in ICU-acquired candidaemia. The primary objective of this study was to evaluate risk factors for the severe presentation (severe sepsis or septic shock) and mortality in patients with candidaemia in ICUs. Secondarily, we compared 28-day mortality between patients treated with fluconazole and those treated with an echinocandin. Methods: A retrospective cohort design was employed in a single-center ICU setting, encompassing a study period from 2004 to 2023. Adult patients who had Candida growth in blood cultures taken 48 h after admission to the ICU were included in the study. Risk factors for the severe presentation (severe sepsis and septic shock) and mortality were evaluated in the 141 patients included in the study. The treatment comparison between fluconazole and echinocandins was performed in 113 patients (with 48-h rules) and 125 patients (without 48-h rules). Results: Among 141 patients, 77 (54.6%) died within 28 days. We found that in the multivariable model, APACHE II score, TPN use, steroid use, and concomitant bacteremia were associated with severe presentation. Each one-point increase in APACHE II score was associated with higher risk of severe presentation (adjusted OR 1.146, 95% CI 1.056–1.242; p = 0.001). TPN use and steroid use were also associated with higher risk (adjusted OR 3.297, 95% CI 1.265–8.590; p = 0.015; and adjusted OR 6.067, 95% CI 1.486–24.768; p = 0.012, respectively). Concomitant bacteraemia was associated with lower odds of severe presentation. Patients with severe presentation (severe sepsis or septic shock) had a higher risk of 28-day mortality than patients with sepsis (adjusted OR 8.06, 95% CI 2.60–25.00; p < 0.001). In the primary cohort (n = 113; overlap weights), 28-day mortality was 49.2% with fluconazole and 52.1% with echinocandin (OR 1.12, 95% CI 0.37–3.45; p = 0.838). Results were consistent in the 125-patient cohort without the 48-h rule (OR 1.40, 95% CI 0.51–3.81; p = 0.508). Conclusions: Each one-point increase in APACHE II score on admission, TPN use, and steroid use was associated with severe presentation in ICU-acquired candidaemia. The severity of the clinical presentation at the onset of candidaemia (presence of severe sepsis or septic shock) was strongly associated with 28-day mortality. No difference in 28-day mortality was detected between fluconazole and echinocandin treatment, but this comparison was imprecise and cannot inform antifungal choice.
Related
- Clinical Factors and Composite Biomarkers Associated with Intensive Care Unit-Acquired Weakness: A Retrospective Cohort Study
- Optimizing Polymyxin B Exposure in Carbapenem-Resistant Organism-Associated Hospital-Acquired Pneumonia: A Retrospective Observational Study.
- Factors associated with 30-day mortality in patients with post-myocardial infarction ventricular septal rupture: a retrospective cohort study
- Bloodstream Infections in Patients with Malignancy: Microbiological Epidemiology, Antimicrobial Resistance, and Factors Associated with Mortality in a Nine-Year Single-Center Retrospective Cohort
- Associated factors and a prognostic model for 28-day mortality in Staphylococcus aureus bloodstream infection : A retrospective cohort study
BibTeX
@article{sisman2026factors,
title = {{Factors Associated with Severe Presentation and Mortality in ICU-Acquired Candidaemia: A 20-Year Single-Centre Retrospective Cohort}},
author = {Ayse Sena Sisman and Ugur Onal and Busra Calisir and Emel Yilmaz and Esra Kazak and Yasemin Heper and Guven Ozkaya and Remzi Iscimen and Cuneyt Ozakin and Beyza Ener and Halis Akalin},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15218597},
url = {https://www.mdpi.com/2077-0383/15/21/8597},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Factors Associated with Severe Presentation and Mortality in ICU-Acquired Candidaemia: A 20-Year Single-Centre Retrospective Cohort
AU - Ayse Sena Sisman
AU - Ugur Onal
AU - Busra Calisir
AU - Emel Yilmaz
AU - Esra Kazak
AU - Yasemin Heper
AU - Guven Ozkaya
AU - Remzi Iscimen
AU - Cuneyt Ozakin
AU - Beyza Ener
AU - Halis Akalin
PY - 2026
DA - 2026/11/04
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218597
UR - https://www.mdpi.com/2077-0383/15/21/8597
AB - Background/Objectives: The risk factors for the severe presentation (severe sepsis or septic shock) are not fully understood in ICU-acquired candidaemia. The primary objective of this study was to evaluate risk factors for the severe presentation (severe sepsis or septic shock) and mortality in patients with candidaemia in ICUs. Secondarily, we compared 28-day mortality between patients treated with fluconazole and those treated with an echinocandin. Methods: A retrospective cohort design was employed in a single-center ICU setting, encompassing a study period from 2004 to 2023. Adult patients who had Candida growth in blood cultures taken 48 h after admission to the ICU were included in the study. Risk factors for the severe presentation (severe sepsis and septic shock) and mortality were evaluated in the 141 patients included in the study. The treatment comparison between fluconazole and echinocandins was performed in 113 patients (with 48-h rules) and 125 patients (without 48-h rules). Results: Among 141 patients, 77 (54.6%) died within 28 days. We found that in the multivariable model, APACHE II score, TPN use, steroid use, and concomitant bacteremia were associated with severe presentation. Each one-point increase in APACHE II score was associated with higher risk of severe presentation (adjusted OR 1.146, 95% CI 1.056–1.242; p = 0.001). TPN use and steroid use were also associated with higher risk (adjusted OR 3.297, 95% CI 1.265–8.590; p = 0.015; and adjusted OR 6.067, 95% CI 1.486–24.768; p = 0.012, respectively). Concomitant bacteraemia was associated with lower odds of severe presentation. Patients with severe presentation (severe sepsis or septic shock) had a higher risk of 28-day mortality than patients with sepsis (adjusted OR 8.06, 95% CI 2.60–25.00; p < 0.001). In the primary cohort (n = 113; overlap weights), 28-day mortality was 49.2% with fluconazole and 52.1% with echinocandin (OR 1.12, 95% CI 0.37–3.45; p = 0.838). Results were consistent in the 125-patient cohort without the 48-h rule (OR 1.40, 95% CI 0.51–3.81; p = 0.508). Conclusions: Each one-point increase in APACHE II score on admission, TPN use, and steroid use was associated with severe presentation in ICU-acquired candidaemia. The severity of the clinical presentation at the onset of candidaemia (presence of severe sepsis or septic shock) was strongly associated with 28-day mortality. No difference in 28-day mortality was detected between fluconazole and echinocandin treatment, but this comparison was imprecise and cannot inform antifungal choice.
SN - 2077-0383
ER -